Create accountLogin

Recent searches

No recent searches

Search options

Only available when logged in.
dmv.community is one of the many independent Mastodon servers you can use to participate in the fediverse.
A small regional Mastodon instance for those in the DC, Maryland, and Virginia areas. Local news, commentary, and conversation.

Administered by:

Server stats:

154
active users

dmv.community: AboutStatusProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.7

#Coronavirus

8 posts6 participants2 posts today
Public
Tom Kindlon

"the results from this analysis suggest among people who were tested for #COVID19, those with a positive test experienced an increased rate of diagnosis of infectious illnesses in the 12 months following"

thelancet.com/journals/laninf/

Image is from latest Science for ME weekly update

@longcovid
#LongCovid #PASC #PwLC #postcovid #postcovid19 #LC #Covidlonghaulers #PostCovidSyndrome #longhaulers #COVIDBrain #NeuroPASC
@covid19 #Coronavirus
#COVID #COVID_19 #COVIDー19 #SARSCoV2
@auscovid19 #auscovid19

The Lancet Infectious Diseases Rates of infection with other pathogens after a positive COVID-19 test versus a negative test in US veterans (November, 2021, to December, 2023): a retrospective cohort study — Miao Cai et al. "the results from this analysis suggest that among people who were tested for COVID-19, those with a positive test experienced an increased rate of diagnosis of infectious illnesses in the 12 months following"
Public
Tom Kindlon

From Germany:

Abnormal Coronary Vascular Response in Patients with #LongCOVID Syndrome – a Case-Control Study Using Oxygenation-Sensitive Cardiovascular Magnetic Resonance

sciencedirect.com/science/arti

Image is from latest Science for ME weekly update

Hashtags:
@longcovid
#PASC #PwLC #postcovid #postcovid19 #LC #Covidlonghaulers #PostCovidSyndrome #longhaulers #COVIDBrain #NeuroPASC

@covid19 #Coronavirus
#COVID19 #COVID #COVID_19 #COVIDー19 #SARSCoV2 #CovidIsNotOver
@auscovid19 #auscovid19

1/

Journal of Cardiovascular Magnetic Resonance Abnormal Coronary Vascular Response in Patients with Long COVID Syndrome – a Case-Control Study Using Oxygenation-Sensitive Cardiovascular Magnetic Resonance — Weberling et al. "This pilot study is the first to show a blunted hemodynamic and myocardial oxygenation response to vasoactive breathing maneuvers during Oxygenation-sensitive CMR in long COVID patients. This simple, non-invasive test may be the first to objectify complaints of affected patients and indicates evidence for the crucial role of the endothelium in the pathophysiology of long COVID."
Public
Tom Kindlon

New US research:

Identifying commonalities & differences between EHR representations of #PASC & ME/CFS in the RECOVER EHR cohort

nature.com/articles/s43856-025

"These findings suggest symptom management approaches to these illnesses could overlap"

@mecfs
#MyalgicEncephalomyelitis #ChronicFatigueSyndrome #MEcfs #CFS #PwME @longcovid
#LongCovid #PwLC #postcovid #postcovid19 #LC #Covidlonghaulers #longhaulers #COVIDBrain #NeuroPASC
@covid19 #Coronavirus
#COVID19 #COVID #COVID_19 #COVIDー19 #SARSCoV2

Screenshot of title, author list, abstract & plain language summary
Public
Tom Kindlon

From Australia:

"WEHI researchers have developed a drug compound that can protect mice from contracting long COVID symptoms.

The world-first study also found the compound can treat acute #COVID with better efficacy than Paxlovid"

eurekalert.org/news-releases/1

@longcovid
#LongCovid #PASC #PwLC #postcovid #postcovid19 #LC #Covidlonghaulers #PostCovidSyndrome #longhaulers #COVIDBrain #NeuroPASC

@covid19 #Coronavirus
#COVID19 #COVID_19 #COVIDー19 #SARSCoV2 #CovidIsNotOver
@auscovid19 #auscovid19

News Release 8-Apr-2025 Tackling the ‘silent pandemic’: breakthrough study puts first long COVID treatment on horizon Peer-Reviewed Publication Walter and Eliza Hall Institute Covid Front image: COVID-19 is caused by the SARS-CoV-2 virus. This image shows antibodies (shown in orange and purple) binding to ‘spike proteins’ on the surface of SARS-CoV-2 virus (shown in teal and yellow). Spike proteins are critical for SARS-CoV-2 to enter human cells, and this can be blocked by specific antibodies – breaking the infection cycle. Credit: WEHI Researchers have shown a new drug compound can prevent long COVID symptoms in mice – a landmark finding that could lead to a future treatment for the debilitating condition. The world-first study found mice treated with the antiviral compound, developed by a multidisciplinary research team at WEHI, were protected from long term brain and lung dysfunction – key symptoms of long COVID. Researchers hope the unprecedented results could lead to clinical trials and the first treatment for the disease in the future. At a glance WEHI researchers have developed a drug compound that can protect mice from contracting long COVID symptoms. The world-first study also found the compound can treat acute COVID with better efficacy than Paxlovid – the leading treatment currently approved for COVID-19. It’s hoped the results could lead to clinical trials and an oral treatment for long COVID in the future.
ExploreLive feeds
About